C N Bash - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

C N Bash

Showing results (1-10 of 14) with videos related to

Pageof 2

Sort By:

Neurology|May 1, 1997

Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRIP A Calabresi, L A Stone, C N Bash, et al.

Multiple Sclerosis (Houndmills, Basingstoke, England)|November 1, 1996

MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapiesH F McFarland, L A Stone, P A Calabresi, et al.

AJNR. American Journal of Neuroradiology|November 5, 1998

Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1bN D Richert, J L Ostuni, C N Bash, et al.

Multiple Sclerosis (Houndmills, Basingstoke, England)|April 26, 2001

Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosisN D Richert, J L Ostuni, C N Bash, et al.

Multiple Sclerosis (Houndmills, Basingstoke, England)|April 25, 2000

MRI and clinical activity in MS patients after terminating treatment with interferon beta-1bN D Richert, M C Zierak, C N Bash, et al.

Neurology|September 11, 2002

Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1bA B Rao, N Richert, T Howard, et al.

Annals of Neurology|February 5, 1998

Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosisF Zipp, M Weller, P A Calabresi, et al.

Neurology|June 1, 1995

Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and ageL A Stone, M E Smith, P S Albert, et al.

Neurology|September 26, 1997

Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measureL A Stone, J A Frank, P S Albert, et al.

Multiple Sclerosis (Houndmills, Basingstoke, England)|March 30, 2005

Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosisM Pulicken, C N Bash, K Costello, et al.

Pageof 2

Search research articles

Showing results (1-10 of 14) with videos related to

Sort By:

Pageof 2

Neurology|May 1, 1997

Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRIP A Calabresi, L A Stone, C N Bash, et al.

Multiple Sclerosis (Houndmills, Basingstoke, England)|November 1, 1996

MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapiesH F McFarland, L A Stone, P A Calabresi, et al.

AJNR. American Journal of Neuroradiology|November 5, 1998

Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1bN D Richert, J L Ostuni, C N Bash, et al.

Multiple Sclerosis (Houndmills, Basingstoke, England)|April 26, 2001

Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosisN D Richert, J L Ostuni, C N Bash, et al.

Multiple Sclerosis (Houndmills, Basingstoke, England)|April 25, 2000

MRI and clinical activity in MS patients after terminating treatment with interferon beta-1bN D Richert, M C Zierak, C N Bash, et al.

Neurology|September 11, 2002

Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1bA B Rao, N Richert, T Howard, et al.

Annals of Neurology|February 5, 1998

Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosisF Zipp, M Weller, P A Calabresi, et al.

Neurology|June 1, 1995

Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and ageL A Stone, M E Smith, P S Albert, et al.

Neurology|September 26, 1997

Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measureL A Stone, J A Frank, P S Albert, et al.

Multiple Sclerosis (Houndmills, Basingstoke, England)|March 30, 2005

Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosisM Pulicken, C N Bash, K Costello, et al.

Pageof 2